Summit Therapeutics

Summit Therapeutics FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Summit Therapeutics (SMMT) as of Nov 22, 2026 is 64.27 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 12.50 % — a change of 414.03% (higher).

FCF Conversion

64.27 %

YoY

414.03%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Summit Therapeutics is 2024 64.27 % . FCF Conversion Rate (FCF/EBITDA) of Summit Therapeutics was 2023 12.50 % . It decreases by 414.03% higher compared to the previous year.

The Summit Therapeutics FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2017
84.71 USD
Jan 1, 2018
-356.26 USD
Jan 1, 2019
72.43 USD
Jan 1, 2020
92.09 USD
Jan 1, 2021
82.28 USD
Jan 1, 2022
53.57 USD
Jan 1, 2023
12.50 USD
Jan 1, 2024
64.27 USD
The Summit Therapeutics FCF Conversion history
YEARFCF ConversionYoY
64.27 %+414.03%
12.50 %-76.66%
53.57 %-34.90%
82.28 %-10.65%
92.09 %+27.13%
72.43 %-120.33%
-356.26 %-520.59%
84.71 %-250.22%
-56.39 %-165.83%
85.65 %-14.42%
100.09 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Summit Therapeutics Stock analysis

What does Summit Therapeutics do? Summit Therapeutics Inc. is a global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines for the treatment of life-threatening and rare diseases. The company is headquartered in Massachusetts, USA and also has offices in Oxford, UK. Summit Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Summit Therapeutics stock

FCF Conversion Rate (FCF/EBITDA) of Summit Therapeutics is 64.27 % in 2024.

FCF Conversion Rate (FCF/EBITDA) of Summit Therapeutics changed from 12.50 % to 64.27 %, representing a 414.03% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Summit Therapeutics since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Summit Therapeutics with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Summit Therapeutics

All Key Metrics — Summit Therapeutics